Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo
View: Text | PDF
Clinical Research and Public Health Immunology Oncology

Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

  • Text
  • PDF
Abstract

BACKGROUND Current clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on the tumor properties, such as programmed cell death ligand 1 expression frequency and tumor mutation burden. Identifying reliable, responsive biomarkers based on the host immunity is necessary to improve the predictive values.METHODS We investigated levels of plasma metabolites and T cell properties, including energy metabolism markers, in the blood of patients with non-small cell lung cancer before and after treatment with nivolumab (n = 55). Predictive values of combination markers statistically selected were evaluated by cross-validation and linear discriminant analysis on discovery and validation cohorts, respectively. Correlation between plasma metabolites and T cell markers was investigated.RESULTS The 4 metabolites derived from the microbiome (hippuric acid), fatty acid oxidation (butyrylcarnitine), and redox (cystine and glutathione disulfide) provided high response probability (AUC = 0.91). Similarly, a combination of 4 T cell markers, those related to mitochondrial activation (PPARγ coactivator 1 expression and ROS), and the frequencies of CD8+PD-1hi and CD4+ T cells demonstrated even higher prediction value (AUC = 0.96). Among the pool of selected markers, the 4 T cell markers were exclusively selected as the highest predictive combination, probably because of their linkage to the abovementioned metabolite markers. In a prospective validation set (n = 24), these 4 cellular markers showed a high accuracy rate for clinical responses of patients (AUC = 0.92).CONCLUSION Combination of biomarkers reflecting host immune activity is quite valuable for responder prediction.FUNDING AMED under grant numbers 18cm0106302h0003, 18gm0710012h0105, and 18lk1403006h0002; the Tang Prize Foundation; and JSPS KAKENHI grant numbers JP16H06149, 17K19593, and 19K17673.

Authors

Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo

×

Figure 4

Particular cellular markers, including mitochondria status, were selected to make up a combinatorial predictive marker.

Options: View larger image (or click on image) Download as PowerPoint
Particular cellular markers, including mitochondria status, were selecte...
(A) Two representative NSCLC samples (nonresponder and responder) showing PD-1 and CCR7 positivity after gating on CD8+ PBMCs (left). Frequency of PD-1hiCD8+ T cells in nonresponders and responders in the 1st samples (right). (B) Representative histograms of Mito SOX on gated CD4+ (black) and CD8+ (red) T cells (left). Ratio of Mito SOX levels in CD8+ and CD4+ T cells (Mito SOX CD8/CD4) for nonresponders and responders in the 1st samples (right). (C) PGC-1αβ of the 1st (black), 2nd (red), and 3rd (blue) samples among CD8+ PBMCs (upper left). MFI of PGC-1αβ between the 1st, 2nd, and 3rd samples (upper right). The solid line and dotted line represent responders and nonresponders, respectively. Fold change of PGC-1αβ expression between nonresponders and responders in the 2nd relative to 1st samples (lower left) and the 3rd relative to 2nd samples (lower right). (D) Frequency of CD4+ T cells among PBMCs in the 1st and 2nd samples (left). The solid line and dotted line represent responders and nonresponders, respectively. Fold change of CD4+ T cell frequency in the 2nd relative to 1st samples between nonresponders and responders (right). Each dot represents 1 patient. Error bars show median and interquartile range. *P < 0.05; **P < 0.01; ****P < 0.0001 by Wilcoxon’s rank-sum test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts